3. The industry “should look like our nation.”
The number one reason why people of color don't participate in clinical trials is because nobody asks them,
said Linda Goler Blount, MPH, CEO of the Black Women's Health Imperative.
To address the problem, BIO launched the BIOEquality Agenda, which focuses on health equity and clinical trial diversity, the talent pipeline, and economic development.
So, what does success look like?
“We will no longer be asking the question, how do we make our clinical trials patient user friendly and/or more diverse,” said Dr. Michelle. “We will have trials that are representative of the patients we are trying to serve.”
“I would love for our industry to look like our nation," she concluded.
More Health Care News:
HHS: HHS, DOD collaborate on plans to purchase Lilly investigational therapeutic to treat COVID-19
“This agreement with Eli Lilly is part of Operation Warp Speed’s efforts to position the federal government to distribute potential therapeutics, allowing faster distribution if trials are successful,” said HHS Secretary Alex Azar.
USA TODAY (Opinion): I'm the FDA point person on COVID-19 vaccines. We'll make sure they're safe and effective.
“We pledge to do our duty to the best of our ability, independently, and without conflicts of interest, and we will be transparent about FDA decisions,” writes Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER).